Gemini Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Gemini Therapeutics's estimated annual revenue is currently $7M per year.
- Gemini Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Gemini Therapeutics has 45 Employees.
- Gemini Therapeutics grew their employee count by 0% last year.
Gemini Therapeutics's People
| Name | Title | Email/Phone |
|---|
Gemini Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Gemini Therapeutics?
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics. For more information, visit www.GeminiTherapeutics.com.
keywords:N/A
N/A
Total Funding
45
Number of Employees
$7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gemini Therapeutics News
Gemini Therapeutics, Inc. (NASDAQ:GMTX) Receives Consensus Rating of Buy from Brokerages. Posted by admin on Apr 26th, 2022.
Gemini Therapeutics has higher earnings, but lower revenue than Assembly Biosciences. Gemini Therapeutics is trading at a lower price-to-...
Gemini Therapeutics (NASDAQ:GMTX) versus Affimed (NASDAQ:AFMD) Critical Review. Posted by admin on Apr 16th, 2022.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27M | 45 | -62% | $281.5M |
#2 | $7.6M | 45 | -6% | $128.2M |
#3 | $3.5M | 45 | 18% | N/A |
#4 | $12.7M | 45 | -18% | N/A |
#5 | $3.7M | 45 | 18% | N/A |